Triple Therapy in COPD: What New Evidence Tells Us About Personalized Treatment

Chronic obstructive pulmonary disease (COPD) affects 100 million people in China—on par with the burden of hypertension and diabetes—and ranks as a top public health priority in China’s Healthy China 2030 plan. The goal of COPD care is clear: ease breathing, prevent flare-ups (exacerbations), slow disease progression, and save lives. Over 50 years, treatment has evolved from short-acting inhalers to today’s “triple therapy”—a combination of three drugs in one daily inhaler. But how do we know who will benefit most from this approach? Yong-Hua Gao of The First Affiliated Hospital of Zhengzhou University and Rong-Chang Chen of Shenzhen Institute of Respiratory Diseases review the latest evidence to guide personalized care.

The Evolution of COPD Treatment

In the 1960s, COPD management relied on short-acting bronchodilators (to open airways), oral theophylline (a lung stimulant), and mucus-thinning drugs. By the 1990s, doctors combined inhaled corticosteroids (ICS) (to reduce airway inflammation) with long-acting beta-2 agonists (LABA) (to keep airways relaxed). The 2000s brought long-acting muscarinic antagonists (LAMA)—another type of bronchodilator. Today’s “fixed triple therapy” merges ICS, LABA, and LAMA into one inhaler. This shift came because many patients still struggled with symptoms, flare-ups, and disease worsening even on dual therapies (like LABA/LAMA or ICS/LABA).

What Trials Tell Us About Triple Therapy

Large, double-blind trials—including IMPACT (New England Journal of Medicine, 2018) and TRIBUTE (Lancet, 2018)—show triple therapy outperforms dual therapies in:

Reducing exacerbations (flare-ups that worsen symptoms and require extra care)
Easing breathlessness and improving daily life
Preserving lung function
Possibly extending survival

But these trials focused on specific groups:

High symptom burden: A COPD Assessment Test (CAT) score ≥10 (measures how much cough, fatigue, and breathlessness affect daily life).
Moderate-to-severe airflow limitation: Forced expiratory volume in 1 second (FEV1)—a key lung function test—below 80% of normal (worse as it drops).
Increased exacerbation risk: At least one moderate-to-severe flare-up yearly while on dual therapy.
Asthma history: Many participants had overlapping asthma and COPD.

A critical finding: The biggest difference in exacerbations between triple therapy and dual LABA/LAMA occurred in the first month. This likely happened because some patients stopped ICS before the trial—triggering early flare-ups. For this reason, triple therapy may work best for people with asthma or prior ICS use.

Biomarkers: Who Benefits Most from ICS?

Recent studies (including analyses of the IMPACT trial) highlight two markers that predict response to ICS-containing triple therapy:

Frequent exacerbations: People who’ve had 2+ moderate flare-ups (needing steroids/antibiotics) or 1+ severe (hospitalization) in the past year.
High blood eosinophils: These white blood cells signal allergic or inflammatory activity. Exacerbations with high sputum or blood eosinophils tend to respond better to ICS.

But there are limitations:

Eosinophil counts are inconsistent—they’re affected by infections, allergies, and drugs. The ideal threshold (e.g., 100 vs. 300 cells/mL) is still debated.
Evidence comes from “post-hoc” analysis (looking back at trial data), not dedicated studies.
Low eosinophils (<100 cells/mL) raise pneumonia risk with ICS, while bacterial exacerbations (caused by germs like Haemophilus influenzae) may not respond to ICS at all.

Guidelines: Step-Up to Triple Therapy

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 guidelines recommend triple therapy as a step-up—not first-line. Here’s their advice:

If you’re on LAMA/LABA (dual bronchodilators) and still have exacerbations, add ICS if eosinophils are ≥100 cells/mL (higher counts mean bigger benefits).
If you’re on ICS/LABA and still have breathlessness or flare-ups, add LAMA.
If you’re on triple therapy but have side effects (like pneumonia) or no benefit from ICS, switch back to LAMA/LABA.

For patients with eosinophils >300 cells/mL, stopping ICS may increase flare-ups—so close monitoring is key. If you have no exacerbation history and low eosinophils (<300 cells/mL), you may be able to stop ICS safely.

Could Triple Therapy Be First-Line for Some?

While guidelines emphasize step-up care, the authors suggest two scenarios where triple therapy might make sense as a first choice (even without strong evidence yet):

Post-severe exacerbation: Patients discharged from the hospital after a severe COPD flare-up, with frequent prior exacerbations and eosinophils ≥300 cells/mL (they’re at high risk of rehospitalization).
New severe obstruction: Patients newly diagnosed with severe airflow limitation (FEV1 <50%), symptoms, frequent exacerbations, and either high eosinophils (≥300 cells/mL) or asthma history.

In both cases, starting triple therapy early—then adjusting based on response—could prevent future flare-ups.

Conclusion: Personalized Care Is Non-Negotiable

Triple therapy is a game-changer for many people with COPD, but COPD is not one-size-fits-all. Its heterogeneity—different types like chronic bronchitis, emphysema, or asthma overlap—means personalized care is essential. We need more research to find precise biomarkers for ICS response, but today’s evidence points to triple therapy for:

Frequent or severe exacerbations
Severe symptoms despite dual therapy
Asthma history or prior ICS use
High blood eosinophils (≥300 cells/mL)

Always work with your doctor to assess how you’re responding. If you have side effects like pneumonia, stopping ICS may be necessary to balance benefits and risks.

This article is based on research by Yong-Hua Gao (The First Affiliated Hospital of Zhengzhou University) and Rong-Chang Chen (Shenzhen Institute of Respiratory Diseases), published in the Chinese Medical Journal in 2021.

doi.org/10.1097/CM9.0000000000001340

Was this helpful?

0 / 0